|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chakravarty G, Mathur A, Mallade P,
Gerlach S, Willis J, Datta A, Srivastav S, Abdel-Mageed AB and
Mondal D: Nelfinavir targets multiple drug resistance mechanisms to
increase the efficacy of doxorubicin in MCF-7/Dox breast cancer
cells. Biochimie. 124:53–64. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Podolski-Renić A, Banković J, Dinić J,
Ríos-Luci C, Fernandes MX, Ortega N, Kovačević-Grujičić N, Martín
VS, Padrón JM and Pešić M: DTA0100, dual topoisomerase II and
microtubule inhibitor, evades paclitaxel resistance in
P-glycoprotein overexpressing cancer cells. Eur J Pharm Sci.
105:159–168. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abraham J, Salama NN and Azab AK: The role
of P-glycoprotein in drug resistance in multiple myeloma. Leuk
Lymphoma. 56:26–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Joshi P, Vishwakarma RA and Bharate SB:
Natural alkaloids as P-gp inhibitors for multidrug resistance
reversal in cancer. Eur J Med Chem. 138:273–292. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guo Q, Cao H, Qi X, Li H, Ye P, Wang Z,
Wang D and Sun M: Research progress in reversal of tumor multi-drug
resistance via natural products. Anticancer Agents Med Chem.
17:1466–1476. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu Y, Yue C, Li J, Wu J, Wang S, Sun D,
Guo Y, Lin Z, Zhang D and Wang R: Enhancement of cisplatin
cytotoxicity by retigeric acid B involves blocking DNA repair and
activating DR5 in prostate cancer cells. Oncol Lett. 15:2871–2880.
2018.PubMed/NCBI
|
|
8
|
Cabral BLS, da Silva ACG, de Ávila RI,
Cortez AP, Luzin RM, Lião LM, de Souza Gil E, Sanz G, Vaz BG,
Sabino JR, et al: A novel chalcone derivative, LQFM064, induces
breast cancer cells death via p53, p21, KIT and PDGFRA. Eur J Pharm
Sci. 107:1–15. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Santos MB, Pinhanelli VC, Garcia MAR,
Silva G, Baek SJ, França SC, Fachin AL, Marins M and Regasini LO:
Antiproliferative and pro-apoptotic activities of 2-and
4-aminochalcones against tumor canine cells. Eur J Med Chem.
138:884–889. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee DH, Jung Jung Y, Koh D, Lim Y, Lee YH
and Shin SY: A synthetic chalcone,
2-hydroxy-2,3,5-trimethoxychalcone triggers unfolded protein
response-mediated apoptosis in breast cancer cells. Cancer Lett.
372:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jandial DD, Blair CA, Zhang S, Krill LS,
Zhang YB and Zi X: Molecular targeted approaches to cancer therapy
and prevention using chalcones. Curr Cancer Drug Targets.
14:181–200. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abu N, Akhtar MN, Yeap SK, Lim KL, Ho WY,
Zulfadli AJ, Omar AR, Sulaiman MR, Abdullah MP and Alitheen NB:
Flavokawain A induces apoptosis in MCF-7 and MDA-MB231 and inhibits
the metastatic process in vitro. PLoS One. 9:e1052442014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Abu N, Mohameda NE, Tangarajoo N, Yeap SK,
Akhtar MN, Abdullah MP, Omar AR and Alitheen NB: In vitro toxicity
and in vivo immunomodulatory effects of flavokawain A and
flavokawain B in Balb/C mice. Nat Prod Commun. 10:1199–1202.
2015.PubMed/NCBI
|
|
14
|
Jandial DD, Krill LS, Chen L, Wu C, Ke Y,
Xie J, Hoang BH and Zi X: Induction of G2M arrest by flavokawain A,
a kava chalcone, increases the responsiveness of
HER2-overexpressing breast cancer cells to herceptin. Molecules.
22:E4622017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang S, Kuang G, Zhao G, Wu X, Zhang C,
Lei R, Xia T, Chen J, Wang Z, Ma R, et al: Involvement of the
mitochondrial p53 pathway in PBDE-47-induced SH-SY5Y cells
apoptosis andits underlying activation mechanism. Food Chem
Toxicol. 62:699–706. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Muthusamy G, Gunaseelan S and Prasad NR:
Ferulic acid reverses P-glycoprotein-mediated multidrug resistance
via inhibition of PI3K/Akt/NF-κB signaling pathway. J Nutr Biochem.
63:62–71. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma H, Cheng L, Hao K, Li Y, Song X, Zhou H
and Jia L: Reversal effect of ST6GAL 1 on multidrug resistancein
human leukemia by regulating the PI3K/Akt pathway and the
expression of P-gp and MRP1. PLoS One. 9:e851132014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Calatozzolo C, Gelati M, Ciusani E,
Sciacca FL, Pollo B, Cajola L, Marras C, Silvani A,
Vitellaro-Zuccarello L, Croci D, et al: Expression of drug
resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human
glioma. J Neurooncol. 74:113–121. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lindamulage IK, Vu HY, Karthikeyan C,
Knockleby J, Lee YF, Trivedi P and Lee H: Novel quinolone chalcones
targeting colchicine-binding pocket kill multidrug-resistant cancer
cells by inhibiting tubulin activity and MRP1 function. Sci Rep.
7:102982017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shin SY, Lee MS, Lee DH, Lee DH, Koh D and
Lee YH: The synthetic compound 2-hydroxy-2,4,6-trimethoxychalcone
overcomes P-glycoprotein-mediated multi-drug resistance in
drug-resistant uterine sarcoma MES-SA/DX5 cells. J Korean Soc Appl
Bi. 58:105–109. 2015. View Article : Google Scholar
|
|
21
|
Komoto TT, Bernardes TM, Mesquita TB,
Bortolotto LFB, Silva G, Bitencourt TA, Baek SJ, Marins M and
Fachin AL: Chalcones repressed the AURKA and MDR proteinsinvolved
in metastasis and multiple drug resistance in breast cancer cell
lines. Molecules. 23:20182018. View Article : Google Scholar
|
|
22
|
Wang H, Jia XH, Chen JR, Wang JY and Li
YJ: Osthole shows the potential to overcome P-glycoprotein-mediated
multidrug resistance in human myelogenous leukemia K562/ADM cells
by inhibiting the PI3K/Akt signaling pathway. Oncol Rep.
35:3659–3668. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao Z, Liao Q, Su M, Huang K, Jin J and
Cao D: AKT and ERK dual inhibitors: The way forward? Cancer Lett.
459:30–40. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han Z, Hong L, Han Y, Wu K, Han S, Shen H,
Li C, Yao L, Qiao T and Fan D: Phospho Akt mediates multidrug
resistance of gastric cancer cells through regulation of P-gp,
Bcl-2 and Bax. J Exp Clin Cancer Res. 26:261–268. 2007.PubMed/NCBI
|
|
25
|
Morishita N, Tsukahara H, Chayama K,
Ishida T, Washio K, Miyamura T, Yamashita N, Oda M and Morishima T:
Activation of Akt is associated with poor prognosis and
chemotherapeutic resistance in pediatric B-precursor acute
lymphoblastic leukemia. Pediatr Blood Cancer. 59:83–89. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saura C, Roda D, Roselló S, Oliveira M,
Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García
JM, Musib L, Budha N, et al: A first-in-human phase I study of the
ATP-competitive AKT inhibitor ipatasertib demonstrates robust and
safe targeting of AKT in patients with solid tumors. Cancer Discov.
7:102–113. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Toledo LM, Lydon NB and Elbaum D: The
structure-based design of ATP-site directed protein kinase
inhibitors. Curr Med Chem. 6:775–805. 1999.PubMed/NCBI
|
|
28
|
Ohnishi K, Yasumoto J, Takahashi A and
Ohnishi T: LY294002, an inhibitor of PI-3K, enhances heat
sensitivity independently of p53 status in human lung cancer cells.
Int J Oncol. 29:249–253. 2006.PubMed/NCBI
|
|
29
|
Imai Y, Yamagishi H, Ono Y and Ueda Y:
Versatile inhibitory effects of the flavonoid-derived PI3K/Akt
inhibitor, LY294002, on ATP-binding cassette transporters that
characterize stem cells. Clin Transl Med. 1:242012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cao P, Liu B, Du F, Li D, Wang Y, Yan X,
Li X and Li Y: Scutellarin suppresses proliferation and promotes
apoptosis in A549 lung adenocarcinoma cells via AKT/mTOR/4EBP1 and
STAT3 pathways. Thorac Cancer. 10:492–500. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jiang W, Chen Y, Song X, Shao Y, Ning Z
and Gu W: Pim-1 inhibitor SMI-4a suppresses tumor growth in
non-small cell lung cancer via PI3K/AKT/mTOR pathway. Onco Targets
Ther. 12:3043–3050. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Teschke R: Kava hepatotoxicity-a clinical
review. Ann Hepatol. 9:251–265. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Teschke R, Qiu SX and Lebot V: Herbal
hepatotoxicity by kava: Update on pipermethystine, flavokavain B,
and mould hepatotoxins as primarily assumed culprits. Dig Liver
Dis. 43:676–681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Narayanapillai SC, Leitzman P, O'Sullivan
MG and Xing C: Flavokawains a and B in kava, not
dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity
in C57BL/6 mice. Chem Res Toxicol. 27:1871–1876. 2014. View Article : Google Scholar : PubMed/NCBI
|
